Combo inhaler lacks evidence for first-line use in asthma: PBAC

The committee has revealed why it refused to fund budesonide-formoterol for mild asthma

Despite new international guidelines recommending combination budesonide-formoterol as first-line for mild asthma, the PBAC says there is a lack of evidence for such advice.


In August, the committee rejected an application from Symbicort sponsor AstraZeneca to fund the budesonide-formoterol fixed-dose combination inhaler for adults and adolescents as an alternative to separate reliever and preventer inhalers.

Australian guidelines say a few patients may be effectively controlled on a short-acting beta2-agonist (SABA) alone but most patients with mild asthma